Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is one of 94 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Jazz Pharmaceuticals PLC to related companies based on the strength of its earnings, valuation, institutional ownership, dividends, profitability, risk and analyst recommendations.
This table compares Jazz Pharmaceuticals PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
|Jazz Pharmaceuticals PLC Competitors||-889.02%||-184.03%||-26.48%|
This is a summary of current ratings for Jazz Pharmaceuticals PLC and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||3||16||0||2.84|
|Jazz Pharmaceuticals PLC Competitors||164||551||1211||16||2.56|
Jazz Pharmaceuticals PLC currently has a consensus price target of $182.84, suggesting a potential upside of 23.63%. As a group, “Biotechnology” companies have a potential upside of 132.18%. Given Jazz Pharmaceuticals PLC’s competitors higher probable upside, analysts clearly believe Jazz Pharmaceuticals PLC has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
88.2% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Jazz Pharmaceuticals PLC and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Jazz Pharmaceuticals PLC||$1.54 billion||$758.97 million||22.93|
|Jazz Pharmaceuticals PLC Competitors||$224.58 million||$58.12 million||-0.98|
Jazz Pharmaceuticals PLC has higher revenue and earnings than its competitors. Jazz Pharmaceuticals PLC is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Jazz Pharmaceuticals PLC has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC’s competitors have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.
Jazz Pharmaceuticals PLC beats its competitors on 9 of the 13 factors compared.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.